ES2402220T3 - Compuestos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11b-hexahidro-2H-pirido[2,1-a]isoquinolin-2-ol sustituidos y métodos relacionados con los mismos - Google Patents
Compuestos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11b-hexahidro-2H-pirido[2,1-a]isoquinolin-2-ol sustituidos y métodos relacionados con los mismos Download PDFInfo
- Publication number
- ES2402220T3 ES2402220T3 ES07864160T ES07864160T ES2402220T3 ES 2402220 T3 ES2402220 T3 ES 2402220T3 ES 07864160 T ES07864160 T ES 07864160T ES 07864160 T ES07864160 T ES 07864160T ES 2402220 T3 ES2402220 T3 ES 2402220T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- isoquinolin
- isobutyl
- pyrido
- dimethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86494406P | 2006-11-08 | 2006-11-08 | |
| US864944P | 2006-11-08 | ||
| PCT/US2007/084176 WO2008058261A1 (en) | 2006-11-08 | 2007-11-08 | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2402220T3 true ES2402220T3 (es) | 2013-04-29 |
| ES2402220T8 ES2402220T8 (es) | 2021-12-23 |
Family
ID=39110526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07864160T Active ES2402220T3 (es) | 2006-11-08 | 2007-11-08 | Compuestos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11b-hexahidro-2H-pirido[2,1-a]isoquinolin-2-ol sustituidos y métodos relacionados con los mismos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8039627B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2081929B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5290185B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101500766B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101553487B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007317242B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0718247B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2668689C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2081929T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA018378B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2402220T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL198250A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009004910A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2081929T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2081929E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008058261A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8039627B2 (en) | 2006-11-08 | 2011-10-18 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
| HUE038158T2 (hu) | 2008-09-18 | 2018-09-28 | Auspex Pharmaceuticals Inc | Deuterizált benzokinolizin származékok vezikuláris monoamin transzporter-2 inhibitorként |
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2012000308A1 (zh) * | 2010-06-29 | 2012-01-05 | 中国药科大学 | 丁苯那嗪的拆分方法 |
| US8351329B2 (en) * | 2010-09-14 | 2013-01-08 | Cisco Technology, Inc. | Universal load-balancing tunnel encapsulation |
| CN102285984B (zh) * | 2010-11-25 | 2012-10-10 | 江苏威凯尔医药科技有限公司 | (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法 |
| WO2012081031A1 (en) | 2010-12-15 | 2012-06-21 | Enaltec Labs Pvt. Ltd. | Process for preparing tetrabenazine |
| CA2883641C (en) | 2012-09-18 | 2021-09-14 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| MX2015009719A (es) * | 2013-01-31 | 2016-08-08 | Auspex Pharmaceuticals Inc | Inhibidores benzoquinolona de vmat2. |
| HK1221645A1 (zh) * | 2013-09-27 | 2017-06-09 | Auspex Pharmaceuticals, Inc. | Vmat2的苯并喹啉抑制剂 |
| CN105873589B (zh) * | 2013-12-03 | 2019-11-01 | 奥斯拜客斯制药有限公司 | 制造苯并喹啉化合物的方法 |
| KR20160111999A (ko) * | 2014-01-27 | 2016-09-27 | 오스펙스 파마슈티칼스, 인코포레이티드 | 소포성 모노아민 수송체 2의 벤조퀴놀린 억제제 |
| CN113413385A (zh) | 2014-02-07 | 2021-09-21 | 纽罗克里生物科学有限公司 | 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 |
| KR20160117596A (ko) | 2014-02-07 | 2016-10-10 | 오스펙스 파마슈티칼스, 인코포레이티드 | 신규 제약 제제 |
| CN106164066B (zh) | 2014-02-13 | 2020-01-17 | 因赛特公司 | 作为lsd1抑制剂的环丙胺 |
| DK3936130T3 (da) * | 2014-05-06 | 2024-03-25 | Neurocrine Biosciences Inc | Doseringsskema for Valbenazin til behandling af hyperkinetiske bevægelsesforstyrrelser |
| AU2016215033B2 (en) * | 2015-02-06 | 2020-06-25 | Neurocrine Biosciences, Inc. | (9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
| JP6932641B2 (ja) | 2015-03-06 | 2021-09-08 | オースペックス ファーマシューティカルズ インコーポレイテッド | 異常不随意運動障害の処置のための方法 |
| CN107660205B (zh) | 2015-04-03 | 2021-08-27 | 因赛特公司 | 作为lsd1抑制剂的杂环化合物 |
| JP6919099B2 (ja) * | 2015-06-23 | 2021-08-18 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 神経学的疾患または障害を処置するためのｖｍａｔ２阻害剤 |
| EA035534B1 (ru) | 2015-08-12 | 2020-06-30 | Инсайт Корпорейшн | Соли ингибитора lsd1 |
| WO2017060870A1 (en) | 2015-10-09 | 2017-04-13 | Hermann Russ | Combination of deuterated levodopa with carbidopa and opicapone for the treatment of parkinson`s disease |
| HRP20240304T1 (hr) * | 2015-10-30 | 2024-05-10 | Neurocrine Biosciences, Inc. | Soli valbenazin dihidroklorida i njihovi polimorfi |
| LT3394057T (lt) | 2015-12-23 | 2022-06-27 | Neurocrine Biosciences, Inc. | Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą) |
| WO2017182916A1 (en) * | 2016-04-22 | 2017-10-26 | Lupin Limited | Novel process for preparation of tetrabenazine and deutetrabenazine |
| ES2811048T3 (es) | 2016-06-29 | 2021-03-10 | Crystal Pharmaceutical Suzhou Co Ltd | Formas cristalinas de NBI-98854, método de preparación para las mismas y uso de las mismas |
| EP3523300A1 (en) * | 2016-10-06 | 2019-08-14 | Assia Chemical Industries Ltd. | Solid state forms of valbenazine |
| EP4400171A3 (en) | 2016-12-02 | 2024-09-11 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating schizophrenia or schizoaffective disorder |
| US10703750B2 (en) | 2017-01-10 | 2020-07-07 | Sandoz Ag | Crystalline valbenazine free base |
| KR20190108146A (ko) | 2017-01-27 | 2019-09-23 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| CA3054238A1 (en) | 2017-02-27 | 2018-08-30 | Sandoz Ag | Crystalline forms of valbenazine salts |
| WO2018164996A1 (en) | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| KR20230003308A (ko) | 2017-03-15 | 2023-01-05 | 오스펙스 파마슈티칼스, 인코포레이티드 | 듀테트라베나진의 유사체, 이의 제조 및 용도 |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| JP7250692B2 (ja) * | 2017-04-01 | 2023-04-03 | アデプティオ ファーマシューティカルズ リミテッド | 運動障害の治療における使用のためのジヒドロテトラベナジン |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| JOP20190239A1 (ar) * | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| US20200179352A1 (en) | 2017-04-26 | 2020-06-11 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| IL309802A (en) | 2017-09-21 | 2024-02-01 | Neurocrine Biosciences Inc | High dose valbenazine formulation and related preparations, methods and kits |
| JP2021502959A (ja) | 2017-10-10 | 2021-02-04 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| CA3081709A1 (en) * | 2017-11-08 | 2019-05-16 | Yuhua Li | Esters of dihydrotetrabenazine |
| WO2019104141A1 (en) | 2017-11-22 | 2019-05-31 | Teva Pharmaceuticals Usa, Inc. | Solid state form of valbenazine |
| EP3733666B1 (en) | 2017-12-26 | 2022-09-21 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of valbenazine di-p-toluenesulfonate, preparation method thereof and use thereof |
| CN110092785A (zh) * | 2018-01-31 | 2019-08-06 | 广东东阳光药业有限公司 | 一种丁苯那嗪的动态拆分方法 |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| WO2019241555A1 (en) * | 2018-06-14 | 2019-12-19 | Neurocrine Biosciences, Inc. | Vmat2 inhibitor compounds, compositions, and methods relating thereto |
| JOP20200336A1 (ar) | 2018-08-15 | 2020-12-22 | Neurocrine Biosciences Inc | طرق إعطاء مثبطات vmat2 معينة |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| WO2020070236A1 (en) | 2018-10-04 | 2020-04-09 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders |
| CA3065236A1 (en) | 2018-12-27 | 2020-06-27 | Apotex Inc. | Novel crystalline form of valbenazine dibesylate |
| WO2020213014A1 (en) | 2019-04-19 | 2020-10-22 | Mylan Laboratories Limited | An improved process for the preparation of valbenazine and its salts |
| US10689380B1 (en) | 2019-07-30 | 2020-06-23 | Farmhispania S.A. | Crystalline forms of valbenazine ditosylate |
| WO2021027792A1 (zh) * | 2019-08-12 | 2021-02-18 | 山东绿叶制药有限公司 | Vmat2抑制剂及其制备方法和应用 |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| CA3150961A1 (en) | 2019-09-13 | 2021-03-18 | John Tucker | Processes for the synthesis of valbenazine |
| CN110698397A (zh) * | 2019-10-28 | 2020-01-17 | 南京红杉生物科技有限公司 | 丁苯那嗪中间体及其合成方法、应用和合成用中间产物 |
| JP2024511053A (ja) | 2021-03-22 | 2024-03-12 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｖｍａｔ２阻害剤および使用方法 |
| US20240239791A1 (en) | 2021-04-26 | 2024-07-18 | Neurocrine Biosciences, Inc. | Processes for the synthesis of valbenazine |
| AU2022302155A1 (en) | 2021-06-30 | 2024-02-08 | Neurocrine Biosciences, Inc. | Valbenazine for use in the treatment of dyskinesia due to cerebral palsy |
| JP2024524324A (ja) | 2021-06-30 | 2024-07-05 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 統合失調症のアドオン処置において使用するためのバルベナジン |
| WO2023172849A1 (en) | 2022-03-07 | 2023-09-14 | Neurocrine Biosciences, Inc. | Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease |
| CN119907800A (zh) | 2022-09-21 | 2025-04-29 | 纽罗克里生物科学有限公司 | 六氢-2H-吡啶并[2,1-a]异喹啉VMAT2抑制剂及其使用方法 |
| WO2025038938A1 (en) | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Valbenazine for use in the treatment of huntington's chorea |
| WO2025038959A1 (en) | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| WO2025096823A1 (en) | 2023-11-01 | 2025-05-08 | Neurocrine Biosciences, Inc. | Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine |
| WO2025188830A1 (en) | 2024-03-06 | 2025-09-12 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| WO2025199234A1 (en) | 2024-03-20 | 2025-09-25 | Neurocrine Biosciences, Inc. | Vmat2 inhibitors and methods of use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3209005A (en) * | 1965-09-28 | Hexahydro-llbh-benzo[a] quinolizines and processes therefor | ||
| US2843591A (en) * | 1958-07-15 | Method for preparing same | ||
| US2852518A (en) * | 1957-05-23 | 1958-09-16 | Parke Davis & Co | Di-substituted quinoline compounds |
| AU7872491A (en) | 1990-05-07 | 1991-11-27 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
| US6610841B1 (en) | 1997-12-18 | 2003-08-26 | Gilead Sciences, Inc. | Nucleotide-based prodrugs |
| US7045543B2 (en) * | 2001-11-05 | 2006-05-16 | Enzrel Inc. | Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites |
| GB2410947B (en) | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| WO2006053067A2 (en) | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
| WO2007005283A2 (en) | 2005-06-29 | 2007-01-11 | Trustees Of Columbia University In The City Of New York | Use of dtbz for imaging endocrine pancreas and beta cell mass in type 1 diabetes |
| GB0514501D0 (en) | 2005-07-14 | 2005-08-24 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| GB0516168D0 (en) | 2005-08-05 | 2005-09-14 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| EP1855677B1 (en) | 2005-08-06 | 2008-12-03 | Cambridge Laboratories (Ireland) Limited | 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses |
| US8039627B2 (en) | 2006-11-08 | 2011-10-18 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
-
2007
- 2007-11-08 US US11/937,445 patent/US8039627B2/en active Active
- 2007-11-08 DK DK07864160.2T patent/DK2081929T3/da active
- 2007-11-08 PL PL07864160T patent/PL2081929T3/pl unknown
- 2007-11-08 EA EA200970461A patent/EA018378B1/ru unknown
- 2007-11-08 BR BRPI0718247-3A patent/BRPI0718247B1/pt active IP Right Grant
- 2007-11-08 ES ES07864160T patent/ES2402220T3/es active Active
- 2007-11-08 CA CA2668689A patent/CA2668689C/en active Active
- 2007-11-08 CN CN2007800395790A patent/CN101553487B/zh active Active
- 2007-11-08 MX MX2009004910A patent/MX2009004910A/es active IP Right Grant
- 2007-11-08 WO PCT/US2007/084176 patent/WO2008058261A1/en not_active Ceased
- 2007-11-08 JP JP2009536493A patent/JP5290185B2/ja active Active
- 2007-11-08 PT PT78641602T patent/PT2081929E/pt unknown
- 2007-11-08 AU AU2007317242A patent/AU2007317242B2/en active Active
- 2007-11-08 EP EP07864160A patent/EP2081929B1/en active Active
- 2007-11-08 KR KR1020097011731A patent/KR101500766B1/ko active Active
-
2009
- 2009-04-21 IL IL198250A patent/IL198250A0/en active IP Right Grant
-
2011
- 2011-09-20 US US13/237,709 patent/US8357697B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101553487A (zh) | 2009-10-07 |
| US20120077839A1 (en) | 2012-03-29 |
| JP5290185B2 (ja) | 2013-09-18 |
| AU2007317242B2 (en) | 2013-08-01 |
| CA2668689A1 (en) | 2008-05-15 |
| CA2668689C (en) | 2015-12-29 |
| WO2008058261A1 (en) | 2008-05-15 |
| US8357697B2 (en) | 2013-01-22 |
| EA018378B1 (ru) | 2013-07-30 |
| KR20090079257A (ko) | 2009-07-21 |
| IL198250A0 (en) | 2009-12-24 |
| JP2010509366A (ja) | 2010-03-25 |
| KR101500766B9 (ko) | 2024-09-25 |
| ES2402220T8 (es) | 2021-12-23 |
| PL2081929T3 (pl) | 2013-06-28 |
| AU2007317242A1 (en) | 2008-05-15 |
| EP2081929A1 (en) | 2009-07-29 |
| MX2009004910A (es) | 2009-07-24 |
| BRPI0718247B1 (pt) | 2021-09-21 |
| CN101553487B (zh) | 2012-06-13 |
| US20080167337A1 (en) | 2008-07-10 |
| EA200970461A1 (ru) | 2009-12-30 |
| BRPI0718247A2 (pt) | 2014-01-07 |
| DK2081929T3 (da) | 2013-04-15 |
| US8039627B2 (en) | 2011-10-18 |
| EP2081929B1 (en) | 2013-01-09 |
| PT2081929E (pt) | 2013-04-15 |
| KR101500766B1 (ko) | 2015-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2402220T3 (es) | Compuestos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11b-hexahidro-2H-pirido[2,1-a]isoquinolin-2-ol sustituidos y métodos relacionados con los mismos | |
| AU2008317375B2 (en) | Deuterated darunavir | |
| ES3037872T3 (en) | Deuterated derivatives of ruxolitinib | |
| AU2006262425B2 (en) | Stereoselective synthesis of amino acid analogs for tumor imaging | |
| CA2715390A1 (en) | Imaging agents for detecting neurological dysfunction | |
| AU2012381042A1 (en) | Carboline and carbazole based imaging agents for detecting neurological dysfunction | |
| CN110139863B (zh) | 作为雌激素受体降解剂的吲哚并取代哌啶类化合物 | |
| EP3519393B1 (en) | Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors | |
| JPH07503703A (ja) | （−）−エゼロリン、（−）−ｎ１−ノルエゼロリンおよび（−）−ｎ１−ベンジルノルエゼロリンの置換フェンゼリンおよびフェニルカルバミン酸塩：特異的アセチルコリンエステラーゼ阻害薬としての使用 | |
| EP3988098A1 (en) | Heterocyclo alkyl compounds used as ccr2/ccr5 antagonist | |
| EA021765B1 (ru) | Производные хиназолиндиона, их получение и их различные терапевтические применения | |
| ES2446644T3 (es) | Inhibidor de recaptación de serotonina y norepinefrina | |
| ES2650139T3 (es) | Compuestos 3-fenilsulfanilmetil-biciclo[3.1.0]hexano 4-sustituidos como antagonistas de mGluR 2/3 | |
| LT4381B (lt) | N-monopakeistų ir n, n'-dipakeistų nesimetrinių ciklinių karbamidų gavimo būdas | |
| BRPI0609158A2 (pt) | alcanamidas substituìdas heterocìclicas úteis como inibidores de renina | |
| CN118302418A (zh) | 一种芳杂环类化合物及其应用 | |
| WO2007096194A1 (en) | Radio-labeled isoxazole derivatives useful for the labeling and diagnostic of hsp90 functionality | |
| CN101360742A (zh) | 具有血清素源性活性和增强的治疗特性的取代苯基哌啶 | |
| WO2024243599A1 (en) | Asymmetric phenylalkylamines | |
| ES2710544B2 (es) | Nuevos compuestos de tipo pirazolona para el diagnóstico de alergias a antibióticos betalactámicos | |
| WO2023023261A1 (en) | Radiofluorinated agents for pet imaging selectively targeting fibroblast activation protein |